CST3 and ovarian cancer: Earlier it was shown that in patients with ovarian cancer, the changes of cysteine protease inhibitor cystatin C were not completely associated with cysteine protease cathepsin B. About 20% of high-molecular-weight inhibitors and 50% of low-molecular-weight inhibitors were free in native ascites fluid (7).